Cost-effectiveness analysis (CEA) is an important component of the economic evaluation of new treatment options. In many clinical and observational studies of costs, censored data pose challenges to the CEA. We consider a special situation where the terminating events for the survival time and costs are different. Traditional methods for statistical inference offer no means for dealing with censored data in these circumstances. To address this gap, we propose a new method for deriving the confidence interval for the incremental cost-effectiveness ratio. The simulation studies and real data example show that our method performs very well for some practical settings, revealing a great potential for application to actual settings in which terminating events for the survival time and costs differ.
INTRODUCTION
With health-care costs surging in an environment of limited resources, economic evaluations of new treatment strategies are becoming more and more prevalent. If a program has higher cost but greater benefit than its competitor, a decision must be made on which of the two programs to adopt. The incremental costeffectiveness ratio (ICER) is designed to measure the trade-off between the costs and health benefits of medical interventions. It is defined as the extra costs incurred for saving one additional year-of-life (YOL). The ICER has been the most widely used tool for cost-effectiveness analysis (CEA) (Zwanziger and others, 2006; Wailoo and others, 2008; McIntosh and others, 2009) .
Analyzing cost data requires advanced statistical methodologies, especially when cost data are censored. Over a decade has passed since scholars recognized that caution should be exercised when using censored cost data, as described in Lin and others (1997) . The authors point out that traditional methods for handling censored survival data, such as the Kaplan-Meier estimator, Log-rank test, and Cox proportional hazards regression are no longer valid for analyzing censored cost data, due to the "induced informative censoring" problem. Additionally, because of censoring, the costs and survival distribution cannot be estimated over the entire health history, unless more assumptions are imposed. Hence, a limited time horizon, such as L (years), is often required, i.e. we measure life-years saved within a limited horizon L, costs within L , and hence ICER within L.
Since the ICER is a ratio statistic with quite a skewed distribution, authors often construct a confidence interval (CI) for the ICER in order to estimate its variability. Researchers have proposed various methods for how to find CIs for the ICER. The most widely used in health service research and the health economic literature are bootstrap methods Tibshirani, 1986, 1993; Hwang, 1995; Mushlin and others, 1998; Jiang and others, 2000; O'Brien and Briggs, 2002; Jiang and Zhou, 2004) ; but one can also adapt Fieller's theorem to censored cost data to obtain the CI for the ICER (Fieller, 1954; Chaudhary and Sterns, 1996; Zhao and Tian, 2001; Wang and Zhao, 2008) . Although many researchers believe that since the Fieller method is based on the large sample normal assumption, the bootstrap methods provide better coverage, Hwang (1995) and Jiang and others (2000) showed that both methods are first-order accurate. Therefore, the Fieller method, if used correctly, can be a reliable and efficient way to compute these CIs.
To obtain the CI for the ICER using Fieller's theorem, we need to estimate not only the mean costs and effectiveness (e.g. life expectancies) and their respective variances, but also their covariance. There are proposed methods for estimating the mean medical costs and related variance, and most of these focus on the time-restricted medical costs (Lin and others, 1997; Bang and Tsiatis, 2000; Zhao and Tian, 2001; O'Hagan and Stevens, 2004; Raikou and McGuire, 2004; Zhao and others, 2007, among others) . In the construction of the CI, a challenge caused by an earlier stopping time for cost collection for some patients has been addressed by Wang and Zhao (2006) . However, another challenge arises when the terminating events for costs and survival are different. For example, in the Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy (MADIT-CRT), the primary goal was to determine whether the CRT with biventricular pacing would reduce the risk of death or heart failure (HF) events in patients with mild cardiac symptoms (Moss and others, 2009) . The terminating event for the effectiveness measure is death or HF, whichever occurs first. Meanwhile, some patients who experienced HF events were still living, and continued to accumulate costs and report these costs. Since the treatment costs accumulated until death is of interest, the terminating event for this cost evaluation is a different one, death. We anticipate that more and more medical advances will occur, which may not prolong the overall survival time, but will prevent adverse events such as HFs. Therefore, ICERs with different terminating events might be used more frequently in the future.
The remainder of the article is organized as follows. In Section 2, we propose a method for estimating the ICER and constructing its CI with censored data and different terminating events. In Section 3, we perform numerical studies to examine the empirical coverage probability of the CI for this special ICER, and compare its performance with bootstrap methods. Next, we illustrate our method by applying it to the MADIT-CRT study. Finally, we provide discussions and concluding remarks.
METHODS

Notation and assumptions
We first concentrate on patients in one arm of the study. For the ith person, let T i denote the overall survival time, i.e. time until death. In addition, the subject may experience a HF event at time HF i . Let T We assume that the censoring time C i is independent of the survival time T i , the HF time HF i , and the cost history process {M i (u), u T i }. This assumption is reasonable for a well-conducted clinical trial. Because of censoring, it is impossible to estimate the costs over the entire health history. Therefore, we consider only costs accumulated up to a maximum of L units of time, where L is chosen based on the availability of data. This is equivalent to redefining our survival time as
For ease of notation, we suppress the superscript * of T * i and T F * i throughout the paper. For each of the two treatment groups, k = 0, 1, we observe the following identically distributed, independent data
n k is the number of patients for arm k. Our goal is to estimate the mean cost μ M = E{M i (T i )} and the mean HF-free survival time μ
for each of the treatment groups, and to compare the treatment strategies by obtaining the ICER and its CI, based on the estimated differences of μ M and μ F from the two groups and their variances and covariances.
Estimating the mean costs for each group
Here, we briefly review the methods for estimating the mean costs accumulated over time L with censored data. Bang and Tsiatis (2000) proposed a consistent estimator based on the inverse probability weighting technique:μ
is the Kaplan-Meier estimator for the survival function of the censoring time C, K (u) = Pr(C i > u). This is the simple unpartitioned version, and Bang and Tsiatis (2000) also provided a partitioned estimator BTp.
When the cost history is available, the BT estimator is not efficient since it does not use the cost information from censored observations. A more efficient estimator, which is also easy to use, is proposed by Zhao and Tian (2001) . The ZT estimator has the following simplified form (Pfeifer and Bang, 2005) :
, which is the average accumulated costs at time C i of those subjects who are alive at C i .
Zhao and others (2007) described the conditions under which the ZT estimator is equivalent to the BTp estimator, as well as the two estimators LinA/B proposed by Lin and others (1997) . Zhao and Tian (2001) show that the ZT estimator is consistent, and asymptotically normally distributed with variance that can be estimated consistently bŷ 2) where
is the Kaplan-Meier estimator for S(u), the survival distribution of T at time u, using . . . , n) . This variance formula is a simplified form of the original formula given by Zhao and Tian (2001) and Zhao and Wang (2010) .
Estimating the mean HF-free survival time for each group
The mean survival time up to time L can be obtained by the area under the survival function, i.e.μ T = L 0Ŝ (x)dx, whereŜ(x) is the Kaplan-Meier estimator for S(u) = Pr(T > u). This estimator can be more conveniently obtained (Satten and Datta, 2001; Zhao and Tian, 2001 ) bŷ
Similarly, the mean HF-free survival time can be estimated bŷ Zhao and Tian (2001) , its variance can be estimated consistently by
where
Estimating the ICER and its CI
The ICER is the ratio of the difference of costs and the difference of effects between two treatment groups. Here, we use HF-free survival time as the measure of effectiveness. For a two-arm trial, for each group k (k = 0, 1), denote μ 
where s xx and s yy are respectively the variances of x and y, s xy is the covariance of x and y, and z α is the cut-off point with tail area α of the standard normal distribution. If the denominator of (2.5) is positive, the CI is finite. If the denominator of (2.5) is negative, meaning that the difference between the effects of two treatments is not statistically significant, the CI for the ICER is exclusive and thus infinite. For a discussion on the interpretation of infinite intervals, see Wang and Zhao (2008) .
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The variances of x and y, s xx and s yy , can be obtained from the results mentioned above, treating two arms as independent samples. The challenge is to find the covariance between x and y, or the covariance between the mean cost estimator and the mean HF-free survival time estimatorμ M k andμ F k , due to the different terminating events used here. In the Appendix of supplementary material available at Biostatistics online, we express the mean HF-free survival time estimatorμ F k and the mean cost estimatorμ M k in martingale forms, and derive the covariance between them based on the counting process theory and the general theory for the missing data process (Fleming and Harrington, 1991; Robins and Rotnitzky, 1992; Robins and others, 1994) . We show that the covariance betweenμ M k andμ F k can be estimated consistently byĈ
SIMULATION
We conduct simulation studies to examine the performance of the covariance formula, and the coverage probability of the CI of the ICER that relies on the covariance formula. The overall survival time has an exponential distribution T ∼ exp(10), which is the same for both treatment groups. The HF time is also exponentially distributed, but is different for each group: HF ∼ exp(6) for Group 0, and HF ∼ exp(12) for Group 1. Hence, Group 1 represents a new treatment which prevents the occurrence of HFs but is not effective in preventing death. The survival time T and HF time HF are generated independently and truncated at L=10. The HF-free survival time is defined as T F = min(T, HF), as mentioned previously. The censoring time has a uniform distribution, C ∼ Unif (0, 15), resulting in 42% censoring for the overall survival time and 24-30% censoring for the HF-free survival time. The true mean HF-free survival time is 3.49 and 4.58 for Group 0 and Group 1, respectively.
We consider U-shaped sample paths for the costs, similarly to Bang and Tsiatis (2000) and Zhao and others (2012) . The entire time period [0, 10] is partitioned into 10 equal (yearly) intervals. The total costs consist of the initial costs incurred at the beginning of the study, the terminal costs accumulated during the last year before death, the fixed annual costs which do not change for each patient, and the random annual costs which vary from year to year. We consider two scenarios with uniformly distributed costs and log-normally distributed costs. For the uniform setting, the initial costs, fixed annual costs, random annual costs, and terminal costs are uniformly distributed in (1,000, 3,000), (2,000, 4,000), (0,400), (5,000, 15,000) for Group 0, and in (20,000, 30,000), (2,000, 3,000), (0,400), (5,000, 15,000) for Group 1. For the log-normal setting, these costs are log-normally distributed with parameters (8.5, 0.632 2 ), (8, 0.245 2 ), (4, 0.245 2 ), and (8, 0.632 2 ) for Group 0, and (10.2, 0.632 2 ), (7.5, 0.245 2 ), (4, 0.245 2 ), and (8, 0.632 2 ) for Group 1. The true mean costs for Group 0 and Group 1 are $28 241 and $48 095 under the uniform setting, and $27 932 and $47 133 under the log-normal setting. Thus, Group 1 is associated with a longer HF-free survival time, but is also more costly than Group 0, mainly due to large initial costs.
The simulation results based on 2000 runs, and various sample sizes, are summarized in Table 1 . We first examine the performance of the covariance estimator. Here SCov represents the sample covariance of SCov is the sample covariance of the mean cost estimator and the mean HF-free survival estimator; ECov is the mean of estimated covariance.
mean costs and mean HF-free survival times, and ECov represents the mean of the estimated covariance using our formula (2.6). As expected, the estimated covariances between the cost estimator and the HF-free survival estimator are very close to the sample covariances. For each run of the simulation study, we calculate also the ICER, the extra costs incurred for saving a year of HF-free survival time, and its CI, within a time limit of L=10 years. We then calculate the coverage probability of the true ICER by the CI over the 2000 simulations, which is also shown in Table 1 . We see that, for various nominal levels, the empirical coverage probability is very close to the nominal level, especially when the sample size is large.
At the suggestion of one reviewer, we also examined the performance of the bootstrap CIs. For our simulation scenarios, the bootstrap samples lie in the Northeast and Northwest regions of the cost-effectiveness (CE) plane. We consider a naive way of constructing the 100(1 − 2α)% CI using the bootstrap percentile method, i.e. arranging the bootstrap ICERs in ascending order, and obtain the 100(1 − 2α)% CI using the upper and lower 100α% cut-off points. We also examine the reordered bootstrap method proposed by Wang and Zhao (2008) , where the orders of ICER are rearranged according to their positions from a CE plane before obtaining the tail cut-off points. The comparison of the three methods is shown in Table 2 . The bootstrap percentile has much higher coverage probabilities than the nominal levels, and this poor performance is due to the fact that it always produces finite intervals, which is incorrect when the difference of the effectiveness between two groups is non-significant. The performance of the reordered bootstrap method is comparable with our method. However, our method runs much faster than the two bootstrap methods (1 min vs 8 h).
A REAL DATA EXAMPLE: MADIT-CRT
In MADIT-CRT study, patients were recruited into the study over time, and were randomized into either the implantable cardiac defibrillator (ICD) arm or the CRT with an ICD (CRT-ICD) arm in a 2:3 ratio. After the trial was completed, it was shown that CRT-ICD reduces the risk of the occurrence of HF or death, especially in patients with a left bundle branch block conduction disturbance (Goldenberg and others, 2011; Zareba and others, 2011 Owing to the huge costs associated with the implantation of an ICD, a CEA also was conducted based on patients from the US centers, with 503 patients in the ICD arm and 748 in the CRT-ICD arm (Noyes and others, 2013) . The goal was to evaluate the CE of the CRT-ICD arm when compared with the ICD only arm, restricted to a 4-year horizon, using both the overall survival time and the HF-free survival time as effectiveness measures.
Cost data were collected and available for analysis with start and stop dates for each entry. These were first discounted at a 3% annual rate and then spread out evenly in the interval. These discounted costs were then used to estimate the mean costs within a 4-year time horizon using the ZT estimator (2.1), separately for the CRT-ICD group, and the ICD group. One hundred and twelve (22%) patients in the ICD arm and 65 (9%) patients in the ICD-CRT arm had HFs but kept accumulating costs, with average additional costs of $35 040 and $28 360, respectively. Each patient's survival time was also discounted at a 3% annual rate, and then plugged in the formulae (2.3) or (2.4) to obtain the average unrestricted YOL, or HF-free YOL, within 4 years. In addition, the ICERs comparing the CRT-ICD group and the ICD group were obtained using both the unrestricted and the HF-free YOL. The results are shown in Table 3 .
The average health-care expenditures in the CRT-ICD group were higher than the ICD-only group ($62 600 vs $57 050, p-value = 0.0146). The CRT-ICD group also had a larger average HF-Free YOL compared with the ICD group, and the difference (0.26 years) was statistically significant ( p-value = 0.0002). These results agreed with the primary study which showed that the CRT-ICD had a significant effect reducing the risk of HF events or death. On the other hand, the difference of unrestricted YOL (0.07 years) was not statistically different ( p-value = 0.1052).
Using the method we proposed, the HF-free ICER comparing the CRT-ICD group with the ICD group was $21 100 (95% CI: 3400, 64 310) per one HF-free YOL saved, which is very close to the bootstrap CI (3380, 62 660) . Figure 1(a) shows the bootstrap samples on the CE plane, as well as the estimated HF-free ICER and 95% CIs. Since the bootstrap samples lie in the Northeast and Southeast regions of the CE plane, we calculated the bootstrap 95% CI by the bootstrap percentile method. The unrestricted ICER comparing the CRT-ICD group with the ICD group was much higher, $80 910 per one overall YOL saved. The 95% CI for the unrestricted ICER using both our method and the bootstrap method consists of infinite intervals due to the non-significance of the difference of unrestricted YOL between the two groups, as shown in Figure 1 (b).
CONCLUSION
In this paper, we consider an important challenge that arises in an actual cost study performed alongside a clinical trial. In a comparison of the CE of a new treatment strategy, the estimates of the effectiveness of the treatment and the costs of the treatment are based on different terminating events. For example, in the MADIT-CRT study, either a HF event or death is used as the terminating event for evaluating the effectiveness of treatment, but death is used for assessing accumulated costs. As in other economic studies conducted in this setting, a censoring problem also complicates the analysis. We provide a method for estimating consistently the covariance between the cost estimator and the survival estimator under this scenario. This method enables us to construct a correct CI for the ICER. Simulation studies show that our covariance estimator and the CIs perform very well for some practical settings. Our method also accommodates discounting for costs and the survival time, and can easily be extended to obtain ICERs and construct their CIs using quality-adjusted life years as a measure of effectiveness.
The method we propose here expands the usefulness of ICERs in more flexible settings. Further work may be performed on incorporating covariate information to estimate ICERs, and developing software to facilitate the use of these new methods.
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